首页> 外国专利> MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells

MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells

机译:MIR-200家族在卵巢癌细胞中诱导间质向上皮转化(MET)

摘要

The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).
机译:本发明提供了一种治疗卵巢癌的方法,该方法包括以有效治疗卵巢癌的量将一个或多个miR-200家族成员递送至需要其的哺乳动物受试者。还提供了预防卵巢癌转移的方法,该方法包括以有效预防转移的量将一个或多个miR-200家族成员递送至需要其的哺乳动物受试者。还提供了使卵巢癌对细胞毒性疗法敏感的方法,该方法包括以有效使卵巢癌对细胞毒性疗法敏感的量向需要其的哺乳动物受试者递送一个或多个miR-200家族成员。本发明还考虑了减少卵巢癌或癌细胞中上皮-间充质转化(EMT)的方法以及诱导间质-上皮转化(MET)的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号